Skip to content
ppharmaranks
Menu
Class IIOngoing

Methylprednisolone acetate Injectable Suspension recall

FDA recall D-0366-2024 · initiated Feb 20, 2024

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Mar 13, 2024How we research

Eugia US LLC recalled Methylprednisolone acetate Injectable Suspension in Feb 2024 — an FDA Class II recall (D-0366-2024) because Failed Dissolution Specifications.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Dissolution Specifications

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot #: 3MA23001, 3MA23002, 3MA23003, Exp 3/31/2025

Quantity recalled: 10,080 vials

Details

Product
Methylprednisolone acetate Injectable Suspension, USP, 400mg per 5mL (80mg/mL, 5mL Multiple-Dose Vial, Rx only, Mfd. in India for: Eugia US LLC, E. Windsor, NJ 08520, NDC 55150-314-01
Recalling company
Eugia Pharma
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
OH, TN, LA, MS
Initiated
Feb 20, 2024
FDA report date
Mar 13, 2024
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Methylprednisolone acetate Injectable Suspension recalled?
Eugia US LLC recalled Methylprednisolone acetate Injectable Suspension in Feb 2024 — an FDA Class II recall (D-0366-2024) because Failed Dissolution Specifications. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Methylprednisolone acetate Injectable Suspension recalled?
Per the FDA enforcement record, the reason for recall D-0366-2024 was: Failed Dissolution Specifications
Is a recalled Methylprednisolone acetate Injectable Suspension dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Methylprednisolone acetate Injectable Suspension are affected?
Distributed: OH, TN, LA, MS. The recall covers these lots — Lot #: 3MA23001, 3MA23002, 3MA23003, Exp 3/31/2025. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0366-2024.

Source: openFDA Drug Enforcement record D-0366-2024

← All drug recalls